Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | CPA3 | P15088 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051091 | 1.00 | MAOB (0.42) | MAOBNPC1RAB9AHPGDOPRK1 | |
| SCHEMBL29505895 | 0.88 | CYP1A2 (0.43) | MAOBCYP1A2CPA1CPB1CPA3 | |
| SCHEMBL13814007 | 0.88 | NPC1 (0.36) | MAOBNPC1RAB9A | |
| SCHEMBL13814005 | 0.88 | NPC1 (0.36) | MAOBNPC1RAB9A | |
| SCHEMBL1493215 | 0.88 | NPC1 (0.36) | MAOBNPC1RAB9A | |
| SCHEMBL438373 | 0.88 | NPC1 (0.36) | MAOBNPC1RAB9A | |
| SCHEMBL16801968 | 0.86 | KMT2A (0.36) | MAOBOPRK1OPRM1OPRD1 | |
| SCHEMBL3108023 | 0.84 | TDP1 (0.42) | MAOBOPRK1OPRM1OPRD1CYP1A2 | |
| SCHEMBL2999347 | 0.84 | TDP1 (0.42) | MAOBOPRK1OPRM1OPRD1CYP1A2 | |
| SCHEMBL2597563 | 0.84 | TDP1 (0.42) | MAOBOPRK1OPRM1OPRD1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1365813-A4 | ASCORBIC ACID ANALOGS FOR METALLORADIOPHARMACEUTICALS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-03-22 | — | — | EP | claimed |
| US-6713042-B2 | BUFFERING REAGENTS, CHELATING AGENTS AND STABILIZERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | claimed |
| EP-1365813-A2 | ASCORBIC ACID ANALOGS FOR METALLORADIOPHARMACEUTICALS | Bristol-Myers Squibb Pharma Company (US) | 2003-12-03 | — | — | EP | claimed |
| WO-2002067859-A3 | ASCORBIC ACID ANALOGS FOR METALLORADIOPHARMACEUTICALS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-11-28 | — | — | WO | claimed |
| WO-2002067859-A2 | ASCORBIC ACID ANALOGS FOR METALLORADIOPHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-09-06 | — | — | WO | claimed |
| US-20020122769-A1 | Ascorbic acid analogs for metalloradiopharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2002-09-05 | — | — | US | claimed |
| EP-1365813-A4 | ASCORBIC ACID ANALOGS FOR METALLORADIOPHARMACEUTICALS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6713042-B2 | BUFFERING REAGENTS, CHELATING AGENTS AND STABILIZERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-1365813-A2 | ASCORBIC ACID ANALOGS FOR METALLORADIOPHARMACEUTICALS | Bristol-Myers Squibb Pharma Company (US) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002067859-A3 | ASCORBIC ACID ANALOGS FOR METALLORADIOPHARMACEUTICALS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002067859-A2 | ASCORBIC ACID ANALOGS FOR METALLORADIOPHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-09-06 | — | — | WO | disclosed |
| US-20020122769-A1 | Ascorbic acid analogs for metalloradiopharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2002-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020122769-A1 | Ascorbic acid analogs for metalloradiopharmaceuticals | SLC40A1, TTPA, SLC39A14 | MAOB 919/4885NPC1 654/4885RAB9A 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.